Manyper (Manidipine Dihydrochloride)

• Manidipine is a dihydropyridine calcium channel blocker indicated for the management of essential hypertension.
• Essential hypertension: lowers systemic vascular resistance, helping to achieve target blood pressure and reduce the risk of cardiovascular events.

• Manidipine selectively blocks L‑type calcium channels in vascular smooth muscle, inhibiting calcium influx. This causes dose‑dependent vasodilation of peripheral arteries, decreasing peripheral vascular resistance and consequently lowering arterial blood pressure without significant negative inotropic effects.

Manidipine may cause a range of adverse reactions. Patients should be informed of common and serious possibilities.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: warm sensation and redness, usually resolves with continued therapy.
• Peripheral edema: swelling of ankles or feet, may require monitoring.
• Dizziness: especially upon standing, related to blood pressure reduction.
• Nausea: occasional gastrointestinal discomfort.
• Tachycardia: increased heart rate in some individuals.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Myocardial infarction: rare occurrence, especially in patients with pre‑existing coronary disease.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Arrhythmias: abnormal heart rhythms, including ventricular ectopy.
• Acute kidney injury: sudden decline in renal function.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal impairment: assess renal function and monitor for fluid retention.
• Hepatic impairment: use with caution; monitor liver enzymes.
• Concomitant antihypertensives: adjust therapy to avoid excessive hypotension.
• Pregnancy: safety not established; avoid unless clearly needed.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at room temperature: keep in the original packaging, protect from moisture and light.

Manidipine may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Other calcium channel blockers: additive vasodilatory effect leading to profound hypotension.
• Grapefruit juice: can elevate drug exposure and risk of side effects.

Moderate Interactions (Monitor Closely):\n- Diuretics: enhanced antihypertensive effect, monitor electrolytes.

• Beta‑blockers: possible bradycardia; observe heart rate.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.